268 related articles for article (PubMed ID: 31781598)
1. A Comprehensive Survey of Genomic Alterations in Gastric Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets.
Chen C; Zhou Q; Wu R; Li B; Chen Q; Zhang X; Shi C
Biomed Res Int; 2019; 2019():2183510. PubMed ID: 31781598
[TBL] [Abstract][Full Text] [Related]
2. Neoantigens Derived from Recurrently Mutated Genes as Potential Immunotherapy Targets for Gastric Cancer.
Zhou J; Zhao W; Wu J; Lu J; Ding Y; Wu S; Wang H; Ding D; Mo F; Zhou Z; Teng L; Chen S
Biomed Res Int; 2019; 2019():8103142. PubMed ID: 31312661
[TBL] [Abstract][Full Text] [Related]
3. Recurrent Neoantigens in Colorectal Cancer as Potential Immunotherapy Targets.
Chen C; Liu S; Qu R; Li B
Biomed Res Int; 2020; 2020():2861240. PubMed ID: 32733937
[TBL] [Abstract][Full Text] [Related]
4. TSNAdb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis.
Wu J; Zhao W; Zhou B; Su Z; Gu X; Zhou Z; Chen S
Genomics Proteomics Bioinformatics; 2018 Aug; 16(4):276-282. PubMed ID: 30223042
[TBL] [Abstract][Full Text] [Related]
5. Identification of shared neoantigens in esophageal carcinoma by the combination of comprehensive analysis of genomic data and in silico neoantigen prediction.
Yuan Y; Chen C; Liu S; Xiong H; Huang Y; Zhang X; Zhang X; Li B
Cell Immunol; 2022 Jul; 377():104537. PubMed ID: 35636066
[TBL] [Abstract][Full Text] [Related]
6. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
[TBL] [Abstract][Full Text] [Related]
7. Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors.
Kim SP; Vale NR; Zacharakis N; Krishna S; Yu Z; Gasmi B; Gartner JJ; Sindiri S; Malekzadeh P; Deniger DC; Lowery FJ; Parkhurst MR; Ngo LT; Ray S; Li YF; Hill V; Florentin M; Masi RV; Paria BC; Levin N; Bera A; Hedges EA; Choi A; Chatani PD; Parikh AY; Levi S; Seitter S; Lu YC; Zheng Z; Prickett TD; Jia L; Hernandez JM; Hoang CD; Robbins PF; Goff SL; Sherry RM; Yang JC; Rosenberg SA
Cancer Immunol Res; 2022 Aug; 10(8):932-946. PubMed ID: 35749374
[TBL] [Abstract][Full Text] [Related]
8. PIK3CA somatic mutations as potential biomarker for immunotherapy in elder or TP53 mutated gastric cancer patients.
Yao J; You Q; Zhang X; Zhang Y; Xu J; Zhao X; Li J; Wang X; Gong Z; Zhang D; Wang W
Clin Genet; 2023 Feb; 103(2):200-208. PubMed ID: 36346122
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of neoantigens derived from structural variation across whole genomes from 2528 tumors.
Shi Y; Jing B; Xi R
Genome Biol; 2023 Jul; 24(1):169. PubMed ID: 37461029
[TBL] [Abstract][Full Text] [Related]
10. Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer.
Karasaki T; Nagayama K; Kawashima M; Hiyama N; Murayama T; Kuwano H; Nitadori J; Anraku M; Sato M; Miyai M; Hosoi A; Matsushita H; Kikugawa S; Matoba R; Ohara O; Kakimi K; Nakajima J
J Thorac Oncol; 2016 Mar; 11(3):324-33. PubMed ID: 26752676
[TBL] [Abstract][Full Text] [Related]
11. [Identification of neoantigens and development of antigen-specific immunotherapy].
Shinohara S; Takahashi Y; Demachi-Okamura A; Matsushita H
Rinsho Ketsueki; 2020; 61(9):1433-1439. PubMed ID: 33162546
[TBL] [Abstract][Full Text] [Related]
12. Unique TP53 neoantigen and the immune microenvironment in long-term survivors of Hepatocellular carcinoma.
Yang H; Sun L; Guan A; Yin H; Liu M; Mao X; Xu H; Zhao H; Lu X; Sang X; Zhong S; Chen Q; Mao Y
Cancer Immunol Immunother; 2021 Mar; 70(3):667-677. PubMed ID: 32876735
[TBL] [Abstract][Full Text] [Related]
13. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens.
Khodadoust MS; Olsson N; Wagar LE; Haabeth OA; Chen B; Swaminathan K; Rawson K; Liu CL; Steiner D; Lund P; Rao S; Zhang L; Marceau C; Stehr H; Newman AM; Czerwinski DK; Carlton VE; Moorhead M; Faham M; Kohrt HE; Carette J; Green MR; Davis MM; Levy R; Elias JE; Alizadeh AA
Nature; 2017 Mar; 543(7647):723-727. PubMed ID: 28329770
[TBL] [Abstract][Full Text] [Related]
14. Identification of Shared Neoantigens in
Ruangapirom L; Sutivijit N; Teerapakpinyo C; Mutirangura A; Doungkamchan C
Vaccines (Basel); 2022 Sep; 10(10):. PubMed ID: 36298462
[TBL] [Abstract][Full Text] [Related]
15. Neoantigen vaccine: an emerging tumor immunotherapy.
Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
[TBL] [Abstract][Full Text] [Related]
16. Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing.
Karasaki T; Nagayama K; Kuwano H; Nitadori JI; Sato M; Anraku M; Hosoi A; Matsushita H; Takazawa M; Ohara O; Nakajima J; Kakimi K
Cancer Sci; 2017 Feb; 108(2):170-177. PubMed ID: 27960040
[TBL] [Abstract][Full Text] [Related]
17. Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens.
Malekzadeh P; Yossef R; Cafri G; Paria BC; Lowery FJ; Jafferji M; Good ML; Sachs A; Copeland AR; Kim SP; Kivitz S; Parkhurst MR; Robbins PF; Ray S; Xi L; Raffeld M; Yu Z; Restifo NP; Somerville RPT; Rosenberg SA; Deniger DC
Clin Cancer Res; 2020 Mar; 26(6):1267-1276. PubMed ID: 31996390
[TBL] [Abstract][Full Text] [Related]
18. Mutation-Derived Neoantigens for Cancer Immunotherapy.
Castle JC; Uduman M; Pabla S; Stein RB; Buell JS
Front Immunol; 2019; 10():1856. PubMed ID: 31440245
[TBL] [Abstract][Full Text] [Related]
19. Neoantigens in cancer immunotherapy.
Schumacher TN; Schreiber RD
Science; 2015 Apr; 348(6230):69-74. PubMed ID: 25838375
[TBL] [Abstract][Full Text] [Related]
20. Utilizing immunogenomic approaches to prioritize targetable neoantigens for personalized cancer immunotherapy.
Shah RK; Cygan E; Kozlik T; Colina A; Zamora AE
Front Immunol; 2023; 14():1301100. PubMed ID: 38149253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
